41基因分类器TRAR预测NeoALTTO研究中HER2阳性乳腺癌患者的治疗反应
本研究基于NeoALTTO试验中226例治疗前肿瘤活检的基因表达数据,评估41基因分类器TRAR预测HER2阳性乳腺癌患者对抗HER2治疗病理完全缓解(pCR)的能力。TRAR水平与pCR显著相关(OR=0.25,95%CI 0.15-0.42),总体AUC为0.73(95%CI 0.67-0.80),且在调整临床病理变量后仍提供独立预测信息。将TRAR加入临床病理变量较加入PAM50具有更高的预测能力(AUC 0.78 vs 0.74,p=0.04)。
要点
- TRAR水平与pCR相关,OR=0.25(95%CI 0.15-0.42)。
- TRAR总体AUC为0.73(95%CI 0.67-0.80)。
- TRAR加入临床病理变量较PAM50提高预测能力(AUC 0.78 vs 0.74,p=0.04)。
核心结论
- TRAR是有前景的工具,可细化识别对抗HER2治疗(包括仅曲妥珠单抗)敏感且适合降阶梯治疗策略的患者。
研究设计与样本
- 基于NeoALTTO试验,获取226例治疗前肿瘤活检的RNA基因表达数据。
- 使用逻辑回归分析和受试者工作特征曲线下面积(AUC)评估TRAR的预测和区分能力。
主要发现
- TRAR水平与pCR相关,OR=0.25(95%CI 0.15-0.42)。
- 总体AUC为0.73(95%CI 0.67-0.80);雌激素受体阳性和阴性病例的AUC分别为0.70(95%CI 0.59-0.81)和0.71(95%CI 0.62-0.80)。
- 曲妥珠单抗、拉帕替尼和联合治疗组的AUC分别为0.74(95%CI 0.60-0.88)、0.76(95%CI 0.65-0.87)和0.71(95%CI 0.59-0.83)。
- TRAR在已建立的临床病理变量之外提供可靠的预测信息(OR=0.26,95%CI 0.14-0.47)。
- 将TRAR加入临床病理变量较加入PAM50提供更高的预测能力:AUC 0.78(95%CI 0.72-0.84)对0.74(95%CI 0.67-0.81),p=0.04。
临床怎么用
- TRAR可用于辅助筛选可能从抗HER2治疗中获益并适合降阶梯治疗的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dual HER2-inhibition combined with neoadjuvant chemotherapy allows increased pathological complete response (pCR) rate. However, with the addition of new agents, there is a growing need to select patients to minimise overtreatment. Herein, we evaluated the 41-gene classifier TRAR to predict pCR to anti-HER2 therapies in the NeoALTTO trial. PATIENTS AND METHODS: Gene expression data were obtained using RNA from 226 pretreatment tumour biopsies. Logistic regression analysis and the area under the receiver operating characteristic (ROC) curve (AUC) were used to evaluate TRAR predictive and discriminatory capabilities. RESULTS: TRAR levels were associated with pCR (odds ratio, OR: 0.25, 95% confidence interval, CI: 0.15-0.42). The ROC analysis showed AUC values of 0.73 (95% CI: 0.67-0.80) overall; 0.70 (0.59-0.81) and 0.71 (0.62-0.80) for positive and negative oestrogen receptor cases and 0.74 (0.60-0.88), 0.76 (0.65-0.87) and 0.71 (0.59-0.83) for trastuzumab, lapatinib and combined treatment arms, respectively. TRAR provided reliable predictive information beyond established clinicopathological variables (OR: 0.26, 95% CI: 0.14-0.47). Furthermore, addition of TRAR to these variables provided greater predictive capability than the addition of PAM50: AUC 0.78 (0.72-0.84) versus 0.74 (0.67-0.81), p = 0.04. CONCLUSION: TRAR represents a promising tool to refine the ability to identify patients sensitive to anti-HER2 (including trastuzumab-only)-based therapy and eligible for de-escalated treatment strategies.
引用
- Di Cosimo S, Triulzi T, Pizzamiglio S, et al. The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. Eur J Cancer. 2019. PMID: 31284184. doi:10.1016/j.ejca.2019.06.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。